Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2003

View Archived Issues

Pharmacopeia and Novartis collaborate on lead compound discovery

Pharmacopeia and Celgene enter inflammatory collaboration

Schering claims novel ligands and metal complexes for use as imaging agents

Novel tyrosine kinase inhibitors in Merck pipeline

Leo Pharma validates psoriasis target from Switch Biotech

Vion awarded SBIR grant for further Tapet studies

Licensing and development activity at Serono

Solvay presents new antiarrhythmic potassium channel blockers

Dual 5-HT2B/H1 antagonist discovered at Biofrontera

Tricyclic antitumor agents covered by Yung Shin patent

Almirall Prodesfarma claims adenosine A2B antagonists for use in asthma and other disorders

Inhibitors of HCV NS5B polymerase identified at GSK

Researchers at Northwestern U. identify novel nNOS inhibitors

InterMune updates idiopathic pulmonary fibrosis programs

Genzyme looks forward to 2003

ZymoGenetics initiates rFXIII phase I trials, signs exclusive licensing agreement

Corixa reacquires North American rights to lung cancer vaccines

Schering AG acquires Japanese and Asian rights to Campath

Millennium submits MAA for Velcade in E.U.

Transition Therapeutics completes acquisition of Stem Cell Therapeutics

Nonamphetamine MAO-B inhibitor protects against MPTP-induced dopamine depletion

Controlled delivery of EYE-001 encapsulated in PLGA microspheres

Improved BBB permeability of NXY-059 under ischemic conditions

BX-471: discovery and preclinical profile discussed at recent scientific meeting

Potent, small-molecule IL-2/IL-2Ralpha antagonist designed at Sunesis

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...